Targeted Therapy for Cancer of Unknown Primary

Targeted therapy is a newer type of cancer treatment that uses drugs or other substances to identify and attack cancer cells while doing little damage to normal cells. These therapies attack the cancer cells’ inner workings – the programming that makes them different from normal, healthy cells. Each type of targeted therapy works differently, but all alter the way a cancer cell grows, divides, repairs itself, or interacts with other cells.

One target on squamous cell cancers of the head and neck is called epidermal growth factor receptor (EGFR). Cells from many of these cancers have too many copies of EGFR, which helps them grow faster and become more resistant to radiation or chemotherapy (chemo). A drug called cetuximab (Erbitux®) blocks EGFR, and can help patients with squamous cell cancers of the head and neck area. It’s often used along with radiation or chemotherapy (chemo), but it can also be used by itself to treat people whose cancers no longer respond to chemo and who can’t take radiation.

A number of targeted therapy drugs are used to treat breast cancer, including trastuzumab (Herceptin®), pertuzumab (Perjeta®), lapatinib (Tykerb®), and everolimus (Affinitor®). For more information, see the section Targeted Therapy for Breast Cancer in our Breast Cancer document.

Other targeted therapy drugs are used for cancers that start in other areas, and may be helpful in some cases of cancer of unknown primary. For example, sunitinib (Sutent®) and everolimus (Afinitor®) are helpful in treating pancreatic neuroendocrine cancer, and may be used to treat well differentiated neuroendocrine cancers of unknown primary.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master’s-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Last Medical Review: July 2, 2014 Last Revised: January 27, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please contact permissionrequest@cancer.org.